This morning, Eagle Pharmaceuticals announced that it has entered into an agreement to acquire Arsia Therapeutics.  According to Arsia’s website, Arsia’s technology enables the production of high-concentration, low-viscosity biologics that can be delivered to patients by subcutaneous injection, autoinjector pen, or patch pump.  Eagle’s press release states that the acquisition of Arsia will mark Eagle’s entry into biologics, and allow Eagle to offer “biobetter” formulations.  Eagle’s President and CEO commented that Eagle intends “to partner with key biosimilar companies to help alter their existing pipelines into biobetters.”

The acquisition is expected to close in the next week.  Eagle will pay approximately $30 million at closing (mix of cash and stock) and has agreed to pay up to $48 million in additional payments.

Stay tuned to Big Molecule Watch for further developments.